These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 32541897)

  • 21. Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs.
    Alabi SB; Crews CM
    J Biol Chem; 2021; 296():100647. PubMed ID: 33839157
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New therapies on the horizon: Targeted protein degradation in neuroscience.
    Gregory JA; Hickey CM; Chavez J; Cacace AM
    Cell Chem Biol; 2024 Sep; 31(9):1688-1698. PubMed ID: 39303702
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proteolysis-targeting chimeras mediate the degradation of bromodomain and extra-terminal domain proteins.
    Yang Y; Wu Z; Chen P; Zheng P; Zhang H; Zhou J
    Future Med Chem; 2020 Sep; 12(18):1669-1683. PubMed ID: 32893690
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protein degradation: a validated therapeutic strategy with exciting prospects.
    Lebraud H; Heightman TD
    Essays Biochem; 2017 Nov; 61(5):517-527. PubMed ID: 28970340
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Potential of Proteolytic Chimeras as Pharmacological Tools and Therapeutic Agents.
    Coll-Martínez B; Delgado A; Crosas B
    Molecules; 2020 Dec; 25(24):. PubMed ID: 33339292
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of inhibitors in the ubiquitination cascade.
    Zhang W; Sidhu SS
    FEBS Lett; 2014 Jan; 588(2):356-67. PubMed ID: 24239534
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PROTAC-DB: an online database of PROTACs.
    Weng G; Shen C; Cao D; Gao J; Dong X; He Q; Yang B; Li D; Wu J; Hou T
    Nucleic Acids Res; 2021 Jan; 49(D1):D1381-D1387. PubMed ID: 33010159
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Time to Get Turned on by Chemical Biology.
    Long MJC
    Chembiochem; 2021 Mar; 22(5):814-817. PubMed ID: 33174365
    [TBL] [Abstract][Full Text] [Related]  

  • 29. VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives.
    Wang C; Zhang Y; Wang J; Xing D
    Eur J Med Chem; 2022 Jan; 227():113906. PubMed ID: 34656901
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted protein degradation mechanisms.
    Zhang Y; Loh C; Chen J; Mainolfi N
    Drug Discov Today Technol; 2019 Apr; 31():53-60. PubMed ID: 31200860
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead.
    Bondeson DP; Smith BE; Burslem GM; Buhimschi AD; Hines J; Jaime-Figueroa S; Wang J; Hamman BD; Ishchenko A; Crews CM
    Cell Chem Biol; 2018 Jan; 25(1):78-87.e5. PubMed ID: 29129718
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    Ohoka N; Okuhira K; Ito M; Nagai K; Shibata N; Hattori T; Ujikawa O; Shimokawa K; Sano O; Koyama R; Fujita H; Teratani M; Matsumoto H; Imaeda Y; Nara H; Cho N; Naito M
    J Biol Chem; 2017 Mar; 292(11):4556-4570. PubMed ID: 28154167
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optochemical Control of Biological Processes in Cells and Animals.
    Ankenbruck N; Courtney T; Naro Y; Deiters A
    Angew Chem Int Ed Engl; 2018 Mar; 57(11):2768-2798. PubMed ID: 28521066
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeted Protein Degradation: An Emerging Therapeutic Strategy in Cancer.
    Barghout SH
    Anticancer Agents Med Chem; 2021; 21(2):214-230. PubMed ID: 32275492
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design and pharmaceutical applications of proteolysis-targeting chimeric molecules.
    Liang Y; Nandakumar KS; Cheng K
    Biochem Pharmacol; 2020 Dec; 182():114211. PubMed ID: 32866456
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Photoactive Bifunctional Degraders: Precision Tools To Regulate Protein Stability.
    Kounde CS; Tate EW
    J Med Chem; 2020 Dec; 63(24):15483-15493. PubMed ID: 33226810
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Haven't got a glue: Protein surface variation for the design of molecular glue degraders.
    Kozicka Z; Thomä NH
    Cell Chem Biol; 2021 Jul; 28(7):1032-1047. PubMed ID: 33930325
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges.
    Zeng S; Huang W; Zheng X; Liyan Cheng ; Zhang Z; Wang J; Shen Z
    Eur J Med Chem; 2021 Jan; 210():112981. PubMed ID: 33160761
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Review of Small Molecule Inhibitors and Functional Probes of Human Cathepsin L.
    Dana D; Pathak SK
    Molecules; 2020 Feb; 25(3):. PubMed ID: 32041276
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Critical Assessment of Targeted Protein Degradation as a Research Tool and Pharmacological Modality.
    Kostic M; Jones LH
    Trends Pharmacol Sci; 2020 May; 41(5):305-317. PubMed ID: 32222318
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.